Fresenius Medical Care (FMS) files 2025 Form 20-F with SEC

Rhea-AI Filing Summary

Fresenius Medical Care, a leading global provider of dialysis products and services, has filed its Annual Report on Form 20-F for fiscal year 2025 with the U.S. Securities and Exchange Commission. The full report, including audited consolidated financial statements, is available on the company’s website and from the SEC.

The company treats individuals with renal diseases through a network of 3,601 dialysis clinics serving approximately 292,000 patients and supports around 4.5 million people worldwide who regularly undergo dialysis. Printed copies of the 20-F can be requested free of charge from the investor relations department.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

For the month of February 2026

Commission file number: 001-32749

FRESENIUS MEDICAL CARE AG

(Translation of registrant's name into English)

Else-Kröner Strasse 1

61346 Bad Homburg

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x                       Form 40-F ¨

EXHIBITS

The following exhibits are being furnished with this Report:

Exhibit 99.1 Press Release issued on February 24, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DATE: February 24, 2026

	Fresenius Medical Care AG
	By:	/s/ Helen Giza
	Name:	Helen Giza
	Title:	Chief Executive Officer and Chair of the Management Board
	By:	/s/ Martin Fischer
	Name:	Martin Fischer
	Title:	Chief Financial Officer and member of the Management Board

Exhibit 99.1

Press Release Media contact Christine Peters T +49 160 60 66 770 christine.peters@freseniusmedicalcare.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 dominik.heger@freseniusmedicalcare.com www.freseniusmedicalcare.com

Fresenius Medical Care published Report on Form 20-F for fiscal year 2025

Bad Homburg (February 24, 2026) – Fresenius Medical Care (FME), the world’s leading provider of products and services for individuals with renal diseases, has filed the Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission (SEC). The report is available at FME’s website (www.freseniusmedicalcare.com) in the “Investors” section as well as on the SEC’s website (www.sec.gov).

A hard copy of FME’s Annual Report on Form 20-F, including the complete audited consolidated financial statements, may be obtained from the Company free of charge upon request to FME’s Investor Relations department by email at ir@freseniusmedicalcare.com.

About Fresenius Medical Care:

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,601 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 292,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company’s website at www.freseniusmedicalcare.com.

Disclaimer:

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various risk factors and uncertainties, including, but not limited to, changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, results of clinical studies, foreign exchange rate and interest rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release. 

Page 1/1

FAQ

What did Fresenius Medical Care (FMS) announce in this Form 6-K filing?

Fresenius Medical Care announced it has filed its 2025 Annual Report on Form 20-F with the SEC. The filing includes the company’s audited consolidated financial statements and is available online through both the company’s website and the SEC’s EDGAR system.

Where can investors access Fresenius Medical Care’s 2025 Form 20-F?

Investors can access the 2025 Form 20-F in the Investors section of Fresenius Medical Care’s website and on the SEC’s website. The company also offers hard copies of the full report, including audited financials, free of charge upon request via its investor relations email.

How can I request a hard copy of Fresenius Medical Care’s 20-F report?

A hard copy of the Annual Report on Form 20-F can be obtained free of charge by contacting Fresenius Medical Care’s Investor Relations department via email at the address provided. The hard copy includes the complete audited consolidated financial statements for fiscal year 2025.

What business does Fresenius Medical Care (FMS) operate according to this filing?

Fresenius Medical Care is described as the world’s leading provider of products and services for individuals with renal diseases. It operates 3,601 dialysis clinics treating about 292,000 patients and supplies dialysis products such as machines and dialyzers to support around 4.5 million dialysis patients globally.

On which stock exchanges is Fresenius Medical Care listed?

Fresenius Medical Care is listed on the Frankfurt Stock Exchange under the symbol FME and on the New York Stock Exchange under the symbol FMS. These dual listings provide access for both European and U.S. investors to trade the company’s shares in their respective markets.

Does this Fresenius Medical Care filing include forward-looking statements?

The filing notes that the accompanying release contains forward-looking statements subject to various risks and uncertainties. It highlights factors such as reimbursement changes, regulatory developments, clinical results, currency and interest rate movements, litigation, cyber security, and financing availability as potential drivers of materially different actual results.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 6.9 KB